List All Prostate Cancer Trials

Prostate Cancer

 

Phenelzine Sulfate and Docetaxel Post First-Line Docetaxel Therapy
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01253642

Degarelix Acetate Prior to Radiation Therapy (7846)
Degarelix Acetate Prior to Radiation Therapy

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01731912

Molecular correlates of sensitivity and resistance to therapy in prostate cancer (UW6932)
Molecular correlates of sensitivity and resistance to therapy in prostate cancer

Investigator: Robert Montgomery, MD;   Conditions: Metastatic Prostate Cancer;    Status: Recruiting;   Study ID: NCT01050504

PASS
Canary Prostate Active Surveillance Study

Investigator: Daniel W. Lin, MD;   Conditions: Prostatic Neoplasms;    Status: Recruiting;   Study ID: NCT00756665

ARN-509 for Relapsed Hormone Sensitive Prostate Cancer (20130917)
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01790126

Provenge+CYT107(IL7) vs. Provenge monotherapy for Metastatic Hormone-Resistant Prostate Cancer (CITN12-03)
A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)

Investigator: Evan Yu, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01881867

Radium-223 Dichloride + Abiraterone for Metastatic Prostate Cancer (Bayer 15-396, UW14012)
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT02043678

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (9328)
PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Investigator: Jing Zeng;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01617161

Cabozantinib in Treating Men With Hormone-Resistant Prostate Cancer (7819)
A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

Investigator: Tia Higano, MD;   Conditions: Prostate Cancer;    Status: Open;   Study ID: NCT01703065

Niclosamide with Enzalutamide for Androgen Receptor Splice Variant-Positive, Castration-Resistant Prostate Cancer (9390)
A Phase I Study of Niclosamide in Combination with Enzalutamide in Men with Androgen Receptor Splice Variant Positive Castration-Resistant Prostate Cancer

Investigator: Michael Schweizer;   Conditions: Prostate Cancer; Solid Tumors; Castration-resistant (CRPC);    Status: Recruiting;   Study ID: NCT02532114

VT-464 for Castration-Resistant Prostate Cancer (20151131)
A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT02445976

Docetaxel + Carboplatin Metastatic Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway
A Pilot Study of Docetaxel and Carboplatin for treatment of patients with metastatic, castration resistant prostate cancer containing biallelic inactivation of genes in the BRCA1/2 pathway

Investigator: Heather Cheng;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT02598895

Sirolimus, Docetaxel and Carboplatin for Metastatic Hormone-Resistant Prostate Cancer (9388)
A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer: (Rapamycin inhibition of DDSP (RID)

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT02565901

AZD8186 Ascending Dose Study for mCRPC (UW13024)
A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumorActivity of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), as Monotherapy and in Combination with Abiraterone Acetate or AZD2014

Investigator: Tia Higano, MD;   Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);;    Status: Recruiting;   Study ID: NCT01884285

Enzalutamide + Leuprolide vs. Enzalutamide + Leuprolide + Abiraterone Acetate + Prednisone for Prostate Cancer (9298)
A phase II randomized study of enzalutamide + leuprolide versus enzalutamide + leuprolide + abiraterone acetate + prednisone as neoadjuvant therapy for high-risk prostate cancer undergoing prostatectomy.

Investigator: Robert Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT02268175

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

Enzalutamide for Castrate-resistant Prostate Cancer
Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostate Cancer;    Status: Recruiting;   Study ID: NCT01942837

ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (SWOG 1216)
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Investigator: Heather H. Cheng, MD, PhD;   Conditions: Prostate Cancer;    Status: Pending;   Study ID: NCT01809691

Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
A Phase I Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)

Investigator: Tia Higano, MD;   Conditions: Prostatic Neoplasms;    Status: Recruiting;   Study ID: NCT02616185